| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
LLY
Eli Lilly & Co
|
Jul 09, 2026 | BUY |
Strong Buy
-13.6% avg upside
47 analysts
|
$1370.00
15.23% Upside
|
-2.3% |
|
PTGX
Protagonist Therapeutics
|
Jul 07, 2026 | BUY |
Strong Buy
-30.7% avg upside
19 analysts
|
$145.00
10.38% Upside
|
-2.3% |
|
ABSI
AbSci
|
Jul 02, 2026 | BUY |
Strong Buy
+14.1% avg upside
18 analysts
|
$17.00
60.39% Upside
|
-8.8% |
|
IVA
Inventiva
|
Jul 02, 2026 | BUY |
Strong Buy
+273.6% avg upside
16 analysts
|
— | +7.7% |
|
INCY
Incyte
|
Jul 02, 2026 | HOLD |
Buy
-14.2% avg upside
47 analysts
|
— | -0.1% |
|
SEPN
Septerna, Inc.
|
Jul 01, 2026 | BUY |
Strong Buy
+27.7% avg upside
12 analysts
|
$43.00
19.62% Upside
|
+5.0% |
|
KYMR
Kymera Therapeutics
|
Jun 29, 2026 | BUY |
Strong Buy
-15.1% avg upside
36 analysts
|
$136.00
13.85% Upside
|
+8.8% |
|
EWTX
Edgewise Therapeutics
|
Jun 17, 2026 | BUY |
Strong Buy
+1.1% avg upside
14 analysts
|
— | +28.2% |
|
MBX
MBX Biosciences, Inc.
|
Jun 15, 2026 | BUY |
Strong Buy
+8.1% avg upside
14 analysts
|
$70.00
14.62% Upside
|
+56.6% |
|
AVAH
Aveanna Healthcare Holdings
|
Jun 08, 2026 | HOLD |
Buy
-6.0% avg upside
17 analysts
|
— | +46.1% |
|
ALT
Altimmune
|
May 29, 2026 | BUY |
Strong Buy
+780.1% avg upside
20 analysts
|
— | · |
|
MDGL
Madrigal Pharmaceuticals
|
May 26, 2026 | BUY |
Strong Buy
-11.3% avg upside
31 analysts
|
$513.59
4.21% Downside
|
+6.0% |
|
ABCL
AbCellera Biologics
|
May 22, 2026 | BUY |
Strong Buy
+93.4% avg upside
15 analysts
|
$12.00
76.52% Upside
|
-7.1% |
|
KROS
Keros Therapeutics
|
May 15, 2026 | BUY |
Strong Buy
+115.7% avg upside
21 analysts
|
— | +0.0% |
|
NAMS
NewAmsterdam Pharma Company
|
May 08, 2026 | BUY |
Strong Buy
+33.1% avg upside
18 analysts
|
— | -7.3% |
|
CYTK
Cytokinetics
|
May 06, 2026 | BUY |
Strong Buy
+3.4% avg upside
36 analysts
|
$106.00
24.90% Upside
|
+13.4% |
|
ARVN
Arvinas Holding Company
|
May 01, 2026 | HOLD |
Buy
+238.0% avg upside
27 analysts
|
$10.00
20.93% Upside
|
-18.6% |
|
BMY
Bristol-Myers Squibb
|
May 01, 2026 | BUY |
Buy
+2.3% avg upside
42 analysts
|
— | +0.0% |
|
OABI
OmniAb
|
Apr 23, 2026 | BUY |
Strong Buy
+239.6% avg upside
10 analysts
|
— | +47.4% |
|
CRIS
Curis
|
Mar 23, 2026 | BUY |
Strong Buy
+72.5% avg upside
12 analysts
|
— | -43.2% |
|
SRRK
Scholar Rock Holding
|
Mar 20, 2026 | BUY |
Strong Buy
+0.2% avg upside
23 analysts
|
— | +30.0% |
|
AMGN
Amgen
|
Nov 05, 2025 | HOLD |
Buy
-17.8% avg upside
57 analysts
|
— | +16.1% |
|
INSM
Insmed
|
Nov 03, 2025 | BUY |
Strong Buy
+50.3% avg upside
36 analysts
|
$214.00
85.08% Upside
|
-37.9% |
|
NRIX
Nurix Therapeutics
|
Oct 30, 2025 | BUY |
Strong Buy
+35.3% avg upside
28 analysts
|
$23.00
0.35% Downside
|
+94.3% |
|
REGN
Regeneron
|
Oct 29, 2025 | BUY |
Strong Buy
+16.2% avg upside
58 analysts
|
$812.00
22.29% Upside
|
+2.2% |
|
CVS
CVS Health
|
Oct 10, 2025 | BUY |
Strong Buy
-1.6% avg upside
39 analysts
|
$84.00
19.39% Downside
|
+37.1% |
|
CHRS
Coherus Biosciences
|
Aug 04, 2025 | HOLD |
Buy
+715.2% avg upside
18 analysts
|
— | +70.5% |
|
BIIB
Biogen
|
Jul 21, 2025 | HOLD |
Strong Buy
+24.2% avg upside
52 analysts
|
$142.00
28.60% Downside
|
+62.3% |
|
BMEA
Biomea Fusion
|
Jul 09, 2025 | HOLD |
Strong Buy
+916.4% avg upside
15 analysts
|
— | -33.4% |
|
MRK
Merck & Company
|
Feb 24, 2025 | HOLD |
Strong Buy
+4.0% avg upside
43 analysts
|
— | +40.9% |
|
ABBV
AbbVie
|
Feb 24, 2025 | HOLD |
Strong Buy
-6.7% avg upside
46 analysts
|
— | +15.7% |
|
PFE
Pfizer
|
Feb 24, 2025 | HOLD |
Buy
+39.2% avg upside
45 analysts
|
— | +9.2% |
|
AFMDQ
Affimed
|
Jan 28, 2025 | HOLD |
Buy
+12648900.0% avg upside
15 analysts
|
— | · |
|
NCNA
Nucana
|
Dec 23, 2024 | HOLD |
Buy
+840.3% avg upside
9 analysts
|
— | -98.6% |
|
RDNT
Radnet
|
Nov 12, 2024 | BUY |
Strong Buy
+22.4% avg upside
10 analysts
|
— | -10.9% |
|
VSTM
Verastem
|
Oct 18, 2024 | BUY |
Strong Buy
+171.9% avg upside
24 analysts
|
$15.00
171.32% Upside
|
+211.5% |
|
NMTRQ
9 Meters Biopharma
|
Mar 20, 2023 | HOLD |
Buy
+3234374900.0% avg upside
11 analysts
|
$38.00
3799999899.99% Upside
|
· |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.